Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shusuke Akamatsu

Showing results (181-190 of 206) with videos related to

Pageof 21
Sort By:
Molecular Cancer Therapeutics|August 28, 2020
Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder CancerYoshihisa Kawai, Kenjiro Imada, Shusuke Akamatsu, et al.
International Journal of Clinical Oncology|February 12, 2025
Prospective observational study on the relationships between genetic alterations and survival in Japanese patients with metastatic castration-sensitive prostate cancer: the impact of IDC-PMasashi Kato, Hiroyuki Sato, Yushi Naito, et al.
European Urology Oncology|June 16, 2019
Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate CancerShusuke Akamatsu, Masashi Kubota, Ryuji Uozumi, et al.
Journal of Cancer Research and Clinical Oncology|September 15, 2017
The usefulness of testosterone administration in identifying false-positive elevation of serum human chorionic gonadotropin in patients with germ cell tumorAkitoshi Takizawa, Koji Kawai, Takashi Kawahara, et al.
Nature Genetics|February 28, 2012
Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in JapaneseShusuke Akamatsu, Ryo Takata, Christopher A Haiman, et al.
Cancer Immunology, Immunotherapy : CII|February 2, 2023
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trialMasaki Shiota, Hideaki Miyake, Masayuki Takahashi, et al.
Cancer Science|September 24, 2025
GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With NivolumabTokiyoshi Tanegashima, Masaki Shiota, Shusuke Akamatsu, et al.
International Journal of Clinical Oncology|July 19, 2024
A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensityHiroshi Fujiwara, Masashi Kubota, Yu Hidaka, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective studyTomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, et al.
British Journal of Cancer|June 7, 2024
Synthetic retinoid-mediated preconditioning of cancer-associated fibroblasts and macrophages improves cancer response to immune checkpoint blockadeTakayuki Owaki, Tadashi Iida, Yuki Miyai, et al.
Pageof 21

Showing results (181-190 of 206) with videos related to

Sort By:
Pageof 21
Molecular Cancer Therapeutics|August 28, 2020
Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder CancerYoshihisa Kawai, Kenjiro Imada, Shusuke Akamatsu, et al.
International Journal of Clinical Oncology|February 12, 2025
Prospective observational study on the relationships between genetic alterations and survival in Japanese patients with metastatic castration-sensitive prostate cancer: the impact of IDC-PMasashi Kato, Hiroyuki Sato, Yushi Naito, et al.
European Urology Oncology|June 16, 2019
Development and Validation of a Novel Prognostic Model for Predicting Overall Survival in Treatment-naïve Castration-sensitive Metastatic Prostate CancerShusuke Akamatsu, Masashi Kubota, Ryuji Uozumi, et al.
Journal of Cancer Research and Clinical Oncology|September 15, 2017
The usefulness of testosterone administration in identifying false-positive elevation of serum human chorionic gonadotropin in patients with germ cell tumorAkitoshi Takizawa, Koji Kawai, Takashi Kawahara, et al.
Nature Genetics|February 28, 2012
Common variants at 11q12, 10q26 and 3p11.2 are associated with prostate cancer susceptibility in JapaneseShusuke Akamatsu, Ryo Takata, Christopher A Haiman, et al.
Cancer Immunology, Immunotherapy : CII|February 2, 2023
Effect of genetic polymorphisms on outcomes following nivolumab for advanced renal cell carcinoma in the SNiP-RCC trialMasaki Shiota, Hideaki Miyake, Masayuki Takahashi, et al.
Cancer Science|September 24, 2025
GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With NivolumabTokiyoshi Tanegashima, Masaki Shiota, Shusuke Akamatsu, et al.
International Journal of Clinical Oncology|July 19, 2024
A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensityHiroshi Fujiwara, Masashi Kubota, Yu Hidaka, et al.
Cancer Immunology, Immunotherapy : CII|June 4, 2024
Combined use of tyrosine kinase inhibitors with PD-(L)1 blockade increased the risk of thyroid dysfunction in PD-(L)1 blockade: a prospective studyTomoko Kobayashi, Shintaro Iwama, Ayana Yamagami, et al.
British Journal of Cancer|June 7, 2024
Synthetic retinoid-mediated preconditioning of cancer-associated fibroblasts and macrophages improves cancer response to immune checkpoint blockadeTakayuki Owaki, Tadashi Iida, Yuki Miyai, et al.
Pageof 21